Latest News - Gastric Cancer Drugs Market: Injectable is expected to lead the Route Of Administration segment during 2025-2029

The Gastric Cancer Drugs Market is being driven by Increasing awareness campaigns for gastric cancer

The Gastric Cancer Drugs Market is expected to grow at a CAGR of 20.6% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 26035 million. The gastric cancer drugs market has witnessed a noteworthy surge in regulatory approvals, with the US Food and Drug Administration (FDA) expediting the process in collaboration with pharmaceutical companies. This strategic partnership has led to expedited approval timelines, from submission to market authorization. In a recent development, in April 2025, the European Union granted marketing authorization to AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as a monotherapy for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer, who have progressed on or are intolerant to at least one endocrine therapy, and are not considered suitable for endocrine therapy as the next line of treatment. This approval underscores the FDA's commitment to expediting the availability of innovative cancer therapies to patients in need. 

Get more information on Gastric Cancer Drugs Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Route Of Administration
  • Injectable
  • Oral
• Distribution Channel
  • Offline
  • Online
• Drug Class
  • Chemotherapy drugs
  • Targeted therapy drugs
  • Immunotherapy drugs
  • Hormonal therapy
• Line of Therapy
  • First-Line
  • Second-Line
  • Third-Line & Beyond
• Diagnosis Type
  • Adenocarcinoma
  • Lymphoma
  • Gastrointestinal Stromal Tumor (GIST)
  • Carcinoid Tumor
  • Others
• End-User
  • Hospitals
  • Specialty Centers
  • Cancer Research Institutes
  • Homecare
• Geography
  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • Italy
    • UK
  • Asia
  • Rest of World (ROW)
    • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increasing awareness campaigns for gastric cancer
• Growing geriatric population globally
• Increasing prevalence of gastric cancer

However, the market also witnesses some limitations, which are as follows:

• High treatment costs of gastric cancer
• Stringent regulations regarding gastric cancer drugs
• Presence of alternative treatment methods

Benefits of Buying Global Gastric Cancer Drugs Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Gastric Cancer Drugs Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Gastric Cancer Drugs Market encompasses treatments for various subtypes, including gastric adenocarcinoma, lymphoma, and stromal tumors. Advanced and metastatic gastric cancer, staged based on tumor microenvironment, require innovative therapies like immune checkpoint inhibitors, angiogenesis inhibitors, and PARP inhibitors. Clinical trials, including randomized controlled studies, analyze data on disease management, drug interactions, healthcare costs, patient access, education, and support services. Effective clinical practice guidelines and quality improvement initiatives are crucial for optimizing care.

Market Research Overview

In the realm of the global pharmaceuticals market, the sector focused on gastric cancer treatments is experiencing significant growth. This segment encompasses companies and researchers involved in the development and manufacturing of both generic and innovative drugs, including targeted therapies and antibody-drug conjugates. The expansion of this market is primarily driven by demographic trends, with the aging population being a key factor. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to be over 60 years old. This demographic shift increases the prevalence of gastric cancer, thereby fueling the demand for advanced treatments such as targeted therapies, which include Her2-positive treatments and antibody-drug conjugates. These innovative therapies offer enhanced efficacy and reduced side effects, making them a promising solution for addressing the unmet medical needs in gastric cancer treatment. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/